Rapamycin Lessens Age‑related Motor Decline, Varies by Sex
Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice 👉"Our results are consistent with the idea that rapamycin’s beneficial effects are mediated, at least in part, by reducing oxidative stress and ER stress-mediated apoptosis... https://t.co/b8EZwrDTXP
Natural SIRT1 Activators May Shield Early Alzheimer’s Microglia
Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation-Energy Axis? 🗣️"We will describe how SIRT1 can represent a key molecular link and an appealing target to harness microglial neuroprotective potential as...
MRK's Sotatercept Shows Inverse Dose Response in 6
$TENX $TECX 🤔 $MRK sotatercept high dose *missed* stat sig on 6MWT in P2 (and it wasn’t particularly close). The low dose hit stat sig (barely) and was the dose taken to P3. What to make of a...
GLP‑1 Drugs Now Help Psoriatic Arthritis Beyond Weight Loss
The list of conditions for which GLP-1 drugs provide benefit independent of weight loss keeps growing. Add psoriatic arthritis #AAD26 @AADskin https://t.co/kJej6osXTS
SGLT2 Inhibitors Help HFrEF Mice via Off‑Target Effects
SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice “The beneficial effects of SGLT2i treatment in gKO mice conclusively demonstrate that in a physiologically relevant preclinical model of HFrEF, SGLT2i can exert therapeutic benefits via off-target pharmacology.3...
Writing Genomes Opens Post‑Darwinian Era of ABI
Artificial Biological Intelligence (ABI) In a post-Darwinian era of being able to write genomes, the implications—both for good and harm—are profound. In conversation with @AdrianWoolfson on his new book On the Future of Species https://t.co/2OahzzxAAa
Published Errors Survive; Faulty Experiments Kill
You can publish a paper with wrong data. You can't make a working drug with a wrong experiment. I wrote about HeLa contamination a few days ago. Then an Oxford researcher told me his story. https://t.co/77vvQQ8kq0
Rejuvenating Blood Stem Cells Boosts Whole‑Body Health
Hematopoietic (stem) cells—The elixir of life? "In this perspective article, we discuss the evidence that supports that rejuvenating or delaying aging of the blood system has a beneficial and systemic impact on human health..." @FEBS_Letters https://t.co/Y9sYcwXp1A @FEBSJournal
DNA Repair Drives Aging; OSK Reverses Epigenetic Decline
Loss of epigenetic information as a cause of mammalian aging “we find that the act of faithful DNA repair advances aging at physiological, cognitive, and molecular levels, including erosion of the epigenetic landscape, cellular exdifferentiation, senescence, and advancement of the DNA...
Epigenetic Dysregulation Fuels Aging, Offers Therapeutic Target
Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target 👉 “By providing mechanistic clarity on how epigenetic dysregulation drives ageing phenotypes, we aim to enable rational design of therapeutics that target the epigenetic systems that fail during ageing,...
Intranasal 5-MeO-DMT Boosts Depression Relief with SSRIs
The results of this first phase 2a clinical trial of intranasal 5-MeO-DMT administered adjunctively to SSRIs demonstrated acceptable safety and tolerability with promising improvements in depressive symptoms. https://t.co/m15DkPP4qX
Senescent Immune Cells Guard Tissues, Delay Aging
Senescent immune cells protect against damage, inflammation and disease 🤯 In mice, p16-expressing immune cells delay age-related organ deterioration and preserve tissue homeostasis. More evidence of the physiological roles of senescent cells? https://t.co/UtBKDF00P1
Hib Vaccine Shields Against Meningitis, Pneumonia, Epiglottitis
The Hib vaccine protects against Haemophilus influenzae type b (Hib) bacteria, which can cause severe illnesses like meningitis, pneumonia, and epiglottitis. Th
FDA Greenlights Viagra: A Pivotal HealthTech Milestone
#ThisDayInTechHistory. March 27, 1998. The FDA approved Viagra developed by Pfizer. (Untold Story) #HealthTech #JVGpost https://t.co/GJea9vd0v9
FDA Confirms Myocarditis Risk, Validating Parents' COVID Concerns
Great thread and one addition: Increased risk of myocarditis in young boys. The demonization of parents who asked, the denials by healthcare professionals and bureaucrats, and ultimately, the admission and subsequent FDA warning proving parents worst fears correct. It will take...
Microbial Phenolics Mediate Oats' Cholesterol‑lowering Power
Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial "Here we show that microbial phenolic metabolites are driving factors for the cholesterol-lowering effect of oats.." https://t.co/Y6fmNYStmZ
PCSK9 Inhibitor Cuts Cardiovascular Events in Diabetics
In a randomized trial of a PCSK9 inhibitor [for LDL cholesterol lowering] vs placebo for patients with diabetes and no known heart disease, there was significant reduction of major cardiovascular events including deaths #ACC26 @JAMA_current https://t.co/mzuI79c4IN https://t.co/16Cpxf7IBx
Supercomputer Maps Spliceosome Dynamics, Advancing Gene‑Splicing Drug Design
Supercomputer simulations of a two-million-atom human cell model have mapped the dynamic motions of the spliceosome, offering detailed insights into gene splicing mechanisms and informing future drug development. computationalbiology
Intensive LDL < 55 Mg/dL Cuts Cardiovascular Events
Validation of aggressive LDL lowering to reduce major adverse cardiovascular events, a randomized trial targeting LDL < 55 mg/dl. In participants with atherosclerotic cardiovascular disease (secondary prevention) @NEJM #ACC26 https://t.co/oLnkqhawOd
AI Meets Scalable Single-Cell Data, Transforming Medicine
AI needs data. And biology is finally generating it at scale. I spoke with @10xGenomics CEO Serge Saxonov about the single-cell and spatial biology revolution — and why the convergence of AI + biological measurement could transform medicine. Read the full profile...
Combining Modest Therapies Unlocks Big Benefits, Reduces Waste
Adam, I used to think this way. Then gene therapy & IO worked. IL2 has consumed a lot of hope; but new variations make it hard to quit. Abeta worked. And synergy: combine modest drugs, unlock big benefits. Invest or...
Retatrutide's Sales Potential Tempered by Heart Risks
I'm fairly sure retatrutide will be the largest peak-sales drug in history (inflation-adjusted). My lingering question is the resting HR elevation of ~5–7 bpm and a 4–14% arrhythmia rate (vs. 2–3% placebo) seen in Phase 2 data, plus insomnia reported...
New Atlas Maps All Human E3 Ligases, Unifying Research
A comprehensive atlas now defines all human E3 ligases, resolving decades of inconsistencies and providing a unified framework to advance research and therapeutic development for diseases linked to these essential enzymes. biotechnology
First Earnings Call Unveils AI‑Driven Aging Therapies
Our first ever earnings call coming up tomorrow - we are reporting our 2025 annual results. I will start the call with the 5 minute introduction to AI drug discovery and how we measure AI drug discovery productivity. In my...
Spanish Team Sustains Human Uterus Alive for 24 Hours
Scientists in Spain kept a donated human uterus alive for 24 hours using a machine that mimics the body's circulatory system, pumping modified blood through the organ.
GLP‑1 Drugs Could Help Prevent Cancer, Study Shows
As a medical school professor, I've watched GLP-1 drugs transform diabetes and obesity treatment. Now a Nature Cancer review reveals they may suppress cancer too. GLP-1 drugs reduce insulin resistance, lower inflammation, and cut body weight -- three of the biggest...
TTN's High Mutation Rate Reflects Size, Not Significance
TTN shows up as one of the most mutated genes in almost every cancer exome. New bioinformaticians see it and think they found something. They didn't. It's a 364-exon gene encoding the largest human protein. It collects mutations like a lint...
Weekly Biotech Roundup: Top Posts Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...
Oral GLP‑1 Battle Heats up Amid FDA Uncertainty
Oral GLP-1 wars, FDA drift, HIV franchise defense, and a few biotech landmines | Ep. 970 https://t.co/sx4kBXzgSL [ 02:30 ] oral GLP-1 battlefield heats up [ 03:08 ] convenience factor drives adoption [ 04:51 ] tolerability issues hit persistence [ 05:45 ] Novo writes $2.1...
AI‑Designed Enzymes Signal SynBio’s Sugar‑Reduction Promise
Can synbio solve sugar reduction? The @ArzedaCo + @ManeGroup partnership is a strong signal. AI-designed enzymes Cell-free manufacturing at scale Real products in market Excited to host Alexandre Zanghellini (@biopraxis) at #SynBioBeta2026. Visit the SynBioBeta website to read the full article: https://t.co/1S29MUqfWh
Β‑Hydroxybutyrate's Dual Impact on Colorectal Cancer
β-Hydroxybutyrate, a primary metabolite of ketogenic diets and its dual role in modulating colorectal cancer: from molecular mechanisms to therapeutic insights https://t.co/pPCdm2AcFo https://t.co/mPtz1Xqiep
From Weight Loss to Longevity: Medicine Shifts Toward Prevention
It’s interesting how quickly the conversation has shifted. Not long ago, people were hesitant about weight loss injections. Now the question is whether GLP-1s should be used… for longevity. That shift alone is worth paying attention to. Because it reflects something deeper — we’re...
Earendil Labs Secures $787M to Accelerate AI Biologics
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development Who is winning AI race again? https://t.co/ZW4S2zUGkS
Repeated Callus Filtering Yields Red Pigment Without
Now THAT is some strong RUBY expression. Filtering transgenic callus a heap of times really pays off. Chasing the red hue without any herbicide or antibiotic pressure. Just hormones to induce callus and careful scalpel work. Some German Chammomile for...
Molecule‑Led Framework Prioritizes Coordination Over Technology
For years, we’ve talked about a trillion-dollar bioeconomy. The harder question has always been where to start. This new piece on the AB4S Molecule Manifesto from @LOrealGroupe, @Lallemande, @EITFood , @BASF, @Evonik, and @cradlebio offers one of the most compelling answers...
New Therapeutic Triad Accelerates Huntington's Disease Breakthroughs
“Huntington’s Disease and The Triad of Therapeutic Conviction”. Debut blog from Eric Green, CEO of Trace Neuro, explaining why and how advances are happening in HD. Genetics, cellular understanding, and enabling modalities. https://t.co/pAr9EQs5gJ
R3 Bio Engineers Whole Organs, Featured in WIRED
This is so awesome. @JohnSchloendorn and Alice Gilman at R3 Bio talk through what they’re doing at R3 Bio: building something that's never existed before. They're designing genetically engineered whole organ systems. See them featured in WIRED. @WIRED full story here: https://t.co/8z5iGXR0uK
Aging Silences Brown Fat's Heat Genes via Epigenetics
Brown fat loses its heat-producing function with age due to epigenetic changes that reduce activity of key genes like PGC1A, with specific enhancers playing a critical role in maintaining this function. https://t.co/Dnnawd5r41
GLP-1 Drugs: Brain‑targeted Cure for Obesity and Addictions
In 1992, scientists discovered a chemical in Gila monster venom that mimicked GLP-1, the hormone your gut releases to signal fullness. By tinkering with its structure, pharma companies extended its duration from two hours (the Gila monster version) to one...
AstraZeneca's Lung Drug Scores Unexpected COPD Trial Win
AstraZeneca lung drug gets ‘surprise’ win in COPD trials https://t.co/QuRlOQtzdT @ByJonGardner $AZN $RGN $SNY $RHHBY
Novartis Acquires Excellergy to Secure Xolair Successor
Novartis targets Xolair successor in buyout of startup Excellergy https://t.co/eGYQ2AxTd5 by @gwendolynawu $NVS $RHHBY #startups #biotech
UCLA Health Omits Patient Polygenic Risk Scores From Study
Kudos to @UCLAHealth for assessing genomics of their patient population, published @CellCellPress today. But why weren't the results of increased polygenic risk scores (PGS) provided to the patient participants? https://t.co/F15isJfDQy https://t.co/3AW7peHa1C
Aging Research Gains Momentum: Collaboration Fuels Therapeutic Breakthroughs
Now at 1M+ views. What struck me most here wasn’t the views. It was the engagement. People are ready to engage seriously with aging biology. Now the opportunity is to turn that energy into stronger collaboration, better translational science, and...
In‑vivo CAR‑T Achieves 4/5 MRD‑Negative Remissions
Outstanding piece here from @leilei_wuu on AstraZeneca's in vivo CAR-T for multiple myeloma. There's data on 5 patients, which is pretty lean, but 4 come out MRD negative in two months, which is extraordinary. We're going to see a lot...
Tech Experts Overestimate Their Grasp of Cancer Biology
As someone who has covered cancer drug development for 25 years, one of the few things I am sure of is that the odds of technology folks thinking they understand biology are much higher than the odds they actually do.
Pharma Rushes Into Psychedelics, M&A Activity Surges
Pharma’s appetite for psychedelic therapies is rapidly accelerating, with M&A interest heating up across the sector.
Decade-Long Quest to Break Blood-Brain Barrier Highlights Biotech Challenges
When we seeded Denali the idea was to break the curse of the blood/brain barrier. It took a decade and tons of faith and money. Biotech is hard. Curing diseases is hard. This is a good summary. ...
Asia Emerges as Testbed for Healthcare Innovation
It was a pleasure to participate in the Investment and Innovation Pathways to a Healthy Asia session at the Global Investors’ Symposium in Hong Kong. A timely discussion on where durable value is being created in healthcare across Asia, from prevention...
AI Empowers Chemists, Accelerating Novel Drug Discovery
The life of a chemist is about to change dramatically as we move away from tedious trial-and-error and deeper into the comfort of the prompt window. We don't need fewer medicinal chemists; we need more high-novelty drugs on the market...
Alpha‑Lipoic Acid Shows Promise for Ischemic Heart Failure
Efficacy of Alpha-Lipoic Acid in Patients With Ischemic Heart Failure: A Double-Blind, Randomized, Placebo-Controlled Study | @JACCJournals https://t.co/nW9SbwEDfy https://t.co/qsemjmMb9k
